Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma [Phase 2]
Phase 2 study update for F520 in locally advanced or metastatic urothelial carcinoma.
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma [Phase 2]
Phase 2 clinical trial update on toripalimab with nab-paclitaxel with or without cisplatin as first-line treatment for urothelial carcinoma.
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma [Phase 2]
Phase 2 clinical trial evaluating genomics-guided therapy selection in advanced urothelial carcinoma/bladder cancer has completed with resul…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]
Phase 2 clinical trial of rucaparib in locally advanced or metastatic urothelial carcinoma was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy [Phase 2]
Phase 2 trial evaluating afatinib as monotherapy in ERBB-deregulated metastatic urothelial tract carcinoma after platinum failure has comple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Cabozantinib for Advanced Urothelial Cancer [Phase 2]
Phase 2 clinical trial of cabozantinib in advanced urothelial cancer has completed and results were posted in 2020.
-
FDA approval · 2020-06-30FDA Approved: BAVENCIO — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for BAVENCIO (avelumab) submitted by EMD Serono, Inc. This entry serves as the official notice of th…
-
FDA approval · 2020-04-02FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for BALVERSA (erdafitinib) from Janssen Products LP, resulting in labeling changes (potentially …
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer [Phase 3]
Phase 3 trial evaluating gemcitabine hydrochloride and cisplatin with or without bevacizumab in advanced urothelial carcinoma/metastatic uro…
-
CLINICAL_TRIALS trial_result · 2020-02-13Clinical Trial Update: A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer [Phase 1, Phase 2]
Clinical trial update evaluating RC48-ADC in combination with JS001 for locally advanced or metastatic urothelial cancer across Phase 1 and …
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 [Phase 2]
Phase 2 trial evaluating imaging of T-cell activation using [18F]F-AraG in urothelial carcinoma patients receiving neoadjuvant therapy or an…
-
FDA approval · 2019-12-18FDA Approved: PADCEV EJFV — Original Application (SEAGEN INC.)
The FDA approved PADCEV EJFV (enfortumab vedotin) from Seagen in its original application, marking the product's initial regulatory clearanc…
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma [Phase 2]
Phase 2 trial evaluating first-line gemcitabine, cisplatin plus ipilimumab for metastatic urothelial carcinoma has completed with posted res…
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function [Phase 2]
Phase 2 trial evaluating vinflunine in patients with metastatic bladder cancer and impaired renal function has completed.
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer [Phase 2]
Phase 2 trial evaluating ACP-196 (calquentinib) in combination with pembrolizumab for metastatic urothelial carcinoma has completed with res…
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) [Phase 3]
Phase 3 trial update for pembrolizumab with epacadostat or placebo in cisplatin-ineligible urothelial carcinoma; results were posted in 2019…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma [Phase 3]
Phase 3 trial comparing pembrolizumab plus epacadostat versus pembrolizumab plus placebo in recurrent or progressive metastatic urothelial c…
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer [Phase 2]
Phase II study of RC48-ADC in HER2-positive metastatic or unresectable urothelial cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy [Phase 2]
Phase 2 trial evaluating MOXR0916 with atezolizumab versus atezolizumab alone in untreated locally advanced or metastatic urothelial carcino…
-
FDA approval · 2019-04-12FDA Approved: BALVERSA — Original Application (Janssen Products LP)
The FDA documents the original approval of BALVERSA (erdafitinib) by Janssen Products LP for urothelial carcinoma with FGFR genetic alterati…
-
CLINICAL_TRIALS trial_result · 2019-04-04Clinical Trial Update: Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer [Phase 2]
Phase 2 trial evaluating vinflunine as maintenance therapy in metastatic urothelial carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-03-08Clinical Trial Update: A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer [Phase 3]
Phase 3 trial evaluating ramucirumab plus docetaxel in urothelial carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-09-26Clinical Trial Update: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma [Phase 1, Phase 2]
Clinical trial update for PD-L1 antibody ZKAB001 in locally advanced and metastatic urothelial carcinoma (Phase 1/2).
-
CLINICAL_TRIALS trial_result · 2018-08-22Clinical Trial Update: Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression [Phase 2]
Phase 2 clinical trial of dovitinib in BCG-refractory urothelial carcinoma with FGFR3 alterations; status terminated with results posted.
-
CLINICAL_TRIALS research · 2018-07-31Clinical Trial Update: The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer [NA]
Clinical trial update on the efficacy of neoadjuvant atezolizumab in advanced urothelial carcinoma; current status is unknown.